outstanding results ., page-6

Hi all - (yes aware our Valve is being tested...................however been tested for some time and it is a mechanical device -possible quicker FDA approval in this case ?????)

Re visiting the Announcements and also one I found very pertinent to the Valve Eires post Post #: 58199493 It is to do with the "laminar Flow" HALT and HAM (worth a look on the web) appears AVR's is more than excellent. From my understanding (I do not hold any more knowledge other than I research...) So do not take my comments "as gospel" but the better the laminar flow the better for the patient -as below

I cannot find on the web, any comments research , that comes close to these Drs comments in last 2 anns below . .....................maybe someone else can! I like the story more and more -

Wonder what the Bench Heart Beats are at now? Must be near 1,000,000,000 at say 70 bpmin that's appx 27 years 75 bpmin that is 25 years
Oh yes and the sheep ?

This is not an improvement on what's available now. I believe it is a replacement 100%

So the 2 biggies that control the market - Wonder their thoughts ? Are they going to let a minnow take their profits ????

Have said before - you as a Dr. and ready to do a valve replacement in future, what valve and procedure -- would you use?

All in my opinion you do your own research .....

The Phantom GWW (hope all cuts and pastes come out OK)
_________________________________________________________________

Why is laminar blood flow important?

The orderly movement of adjacent layers of blood flow through a vessel helps to reduce energy losses in the flowing blood by minimizing viscous interactions between the adjacent layers of blood and the wall of the blood vessel. Disruption of laminar flow leads to turbulence and increased energy losses.

Part from AVR Ann 1-12-21
“ Our patients have passed the 7-day follow up period and all patients are doing well. We are
pleased to see our early observations during the procedures continue and the patient’s
clinical status is excellent. The next milestone will be the 30 day follow up and we look
forward to reviewing the patients at that time” commented Dr Chris Meduri CMO.

Part from AVR Ann 22-11-21
“In this early experience, DurAVR™ showed superior haemodynamics with some of the
largest EOAs (effective orifice areas) I have seen in any TAVR platform. Remarkably, this
was observed with rapid deployment techniques and standard implant depths and in small
aortic annular areas. Importantly, there were no adverse events. This technology allows us
to provide superior haemodynamics with a balloon expandable platform,” Dr Paul Sorajja
said.
“The meticulous preparation for this study has led to an outstanding set of results and patient
outcomes. Not only did the valve performance exceed our very high expectations but the
additional aspects of commissural alignment, flow characteristics and haemodynamics were
proven to be clinically significant. We are excited to now add more patients to our studies in
2022,” Anteris CMO, Dr Chris Meduri, added.